Mirum Pharmaceuticals, Inc. stock is up 13.04% since 30 days ago. The next earnings date is Mar 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 80% of the previous 4 December’s closed higher than November. In the last 2 Unusual Options Trades, there were 2 CALLs. 100% of analysts rate it a buy.
Mirum Pharmaceuticals, Inc. focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease.